Ophthalmic suspension composition
US10596107B2 · kind B2 · utility
0Cited by
14References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 26, 2016 |
| Grant date | Mar 24, 2020 |
| Priority date | — |
| Expiry date | Dec 23, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having Dv90<5 μm and Dv50<1 μm. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.